5 Key Takeaways

• 1

  Mayo Clinic and Thermo Fisher Scientific launched Precure, LLC, to study biological changes that occur before disease symptoms emerge.

• 2

  Precure plans to generate molecular data from 1 million biospecimens and link it with clinical information collected over several years.

• 3

  The initiative will combine proteomic, genomic, and longitudinal clinical data and use artificial intelligence and analytics to identify biological patterns.

• 4

  Thermo Fisher will contribute proteomics expertise and technologies, including the Olink Explore HT platform and Thermo Scientific Orbitrap Mass Spectrometry.

• 5

  Mayo Clinic will hold a majority stake, and financial returns will be reinvested in its nonprofit missions of patient care, research, and education.